Accessibility StatementSkip Navigation Phase 3 AQUILA study showed DARZALEX FASPRO significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring  Landmark approval supports earlier intervention and disease interception of multiple myeloma for the first time HORSHAM, Pa., Nov. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO (daratumumab and hyaluronidase ...